Skip to main content
FinSpry Logo
FinSpry
PLX logo
PLX
(NYSEAMERICAN)
Protalix BioTherapeutics, Inc.
$2.15-- (--)
Loading... - Market loading
OverviewFinancialsForecastStatisticsDividendsHistoricalProfile

Protalix BioTherapeutics (PLX) Stock Price & Financial Analysis

Protalix BioTherapeutics Stock Price Chart

Price Chart

Loading chart...

Financial Metrics & Key Statistics

Fundamental metrics, valuation ratios, and profitability indicators

Day's Range$2.07 - $2.16
52-Week High$3.19
52-Week Low$1.32
Open$2.15
Volume1.10M
Average Volume (3M)1.10M
Market Cap173.75M
Shares Outstanding80.81M
P/E Ratio (TTM)32.81
Price to Sales (P/S)2.86
Price to Book (P/B)3.35
EV/EBITDA19.33
Revenue (TTM)61.84M
Net Income (TTM)5.39M
Free Cash Flow (TTM)-11.69M
EPS (TTM)$0.07
Profit Margin8.72%
Operating Margin10.30%
Return on Equity (ROE)10.20%
Debt to Equity0.15
50-Day MA$2.60
200-Day MA$2.02
52-Week Change-13.78%
Annual Dividend$0.00
Dividend Yield0.00%
Payout Ratio0.00%

Frequently Asked Questions About Protalix BioTherapeutics

What is the current stock price for PLX?

As of the latest trading session, PLX stock trades at $2.15. The 52-week range is $1.32–$3.19, with a day range of $2.07–$2.16.

What is the P/E ratio for PLX?

Protalix BioTherapeutics's trailing P/E ratio is 32.8, meaning investors pay $32.8 for every $1 of annual earnings. Protalix BioTherapeutics operates in the Healthcare sector.

Does PLX pay dividends?

Protalix BioTherapeutics does not currently pay a regular dividend. The company reinvests earnings into growth and operations. Check the Dividends tab for historical dividend information.

What do analysts recommend for PLX?

Based on 1 analyst, the consensus for PLX is Buy. The average 12-month price target is $NaN, representing a NaN% downside from the current price.

What is the market cap of PLX?

Protalix BioTherapeutics's market capitalization is $173.8M, classifying it as a micro-cap company. Protalix BioTherapeutics operates in the Healthcare sector within the Biotechnology industry.